Targacept (TRGT) -15% premarket after the antidepressant it was testing with AstraZeneca (AZN)...
Targacept (TRGT) -15% premarket after the antidepressant it was testing with AstraZeneca (AZN) failed in its last two late-stage studies, ending plans to seek regulatory approval. The two companies said on Dec. 20 the drug hadn’t met its target in a late-stage trial, and the latest failure was the final of four trials on the therapy.
From other sites
at MarketWatch.com (Dec 17, 2013)
at MarketWatch.com (Dec 16, 2013)
at MarketWatch.com (Sep 18, 2012)
at MarketWatch.com (Mar 20, 2012)
at MarketWatch.com (Dec 20, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs